<< Back To Search

In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT05093335
Age 18 +
Sex Both
Phase Early Phase 1
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients. The study focuses on a combination of therapies that target specific aspects of the disease, aiming to improve patient outcomes. Here are some key details about the study:
  • The treatment involves a unique combination of agents that work together to enhance effectiveness.
  • It includes both established and novel therapies, which may provide a broader range of benefits.
  • The study is designed to assess how well this combination works compared to standard treatments.
  • Patients will be monitored closely to evaluate their response to the treatment and any side effects.
  • This approach aims to personalize therapy based on individual patient characteristics, potentially leading to better results.
Overall, this study represents an innovative effort to improve treatment options and outcomes for patients, focusing on a tailored approach that could make a significant difference in managing the disease.
Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: